Family 이모코그 경도인지장애 디지털 치료제 개발

Market position

The company frames its focus on dementia, noting that around 10% of older adults have dementia and that mild cognitive impairment, the pre-dementia stage, has a prevalence of about 25% and progresses over roughly five years. It positions Cogthera as the first domestic cognitive intervention therapy software for MCI in Korea and as Korea's 35th designated innovative medical device.

Products are built on two decades of academic research and peer-reviewed clinical studies in metamemory training, use a voice-conversation interface designed for ease of use by MCI patients, and hold Korean innovative medical device designation; Happymind's CAT is described as the only domestic attention test certified by the Korean Academy of Child and Adolescent Psychiatry.

Technology

Emocog's core technology is multi-strategic metamemory training (MMT), delivered in part through voice/conversational interfaces including smart speakers, which allow training without spatial constraints or expert supervision. The company states its approach rests on roughly 20 years of research with clinical results published in five SCI or SCI-class brain-disease journals, including a case-control cohort study of smart speaker-based metamemory training (Kim et al., Journal of Medical Internet Research, 2021) reporting gains in memory, executive function and working memory; a study of 113 MCI patients (Youn et al., Journal of Clinical Medicine, 2020) reporting significant improvement in delayed free recall and fluency and reduced subjective memory complaints; a randomized controlled trial in 201 adults aged 55+ with subjective memory complaints (Youn et al., Brain and Behavior, 2019) reporting cognitive improvements plus increased white-matter integrity and prefrontal cortical thickness; a neuroimaging analysis of cognitive-improvement predictors (Park et al., Scientific Reports, 2018); and the original Korean MMT program development study (Youn et al., Geropsychiatry, 2011). Assessment products are web-based and device- and OS-agnostic, and Cogthera adapts training difficulty to patient performance.

Go-to-market

Domestic clinical and regulatory pathway in Korea for Cogthera plus simultaneous pursuit of the German DiGA fast-track process with BfArM and CE marking for European entry; the learning-disability line is developed and commercialized with Happymind, whose CAT has significant domestic market share.

Older adults at risk of or diagnosed with mild cognitive impairment and dementia, and the clinicians who screen and prescribe for them; through Happymind, children, adolescents and adults assessed for attention deficits and learning disorders, including educational institutions using the shortened sCAT.

Geography

Headquartered in Korea with a German subsidiary team supporting European market entry; product lines are localized for Korea (Cogthera KR) and Germany (Cogthera DE).

History

The company was founded by medical school professors and has since built a dementia-focused product portfolio spanning screening, diagnosis and treatment, and expanded into learning-disability assessment and treatment through collaboration with Happymind, developer of the CAT.